The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly
upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer …

Hepatocellular carcinoma (HCC) is a highly prevalent, treatment-resistant malignancy with a
multifaceted molecular pathogenesis. Current evidence indicates that during …

The epidermal growth factor receptor (EGFR) is one of most potent oncogenes that are
commonly altered in cancers. As a receptor tyrosine kinase, EGFR's kinase activity has been …

Doxorubicin (DOX)-induced toxicity and resistance are major obstacles in chemotherapeutic
approaches. Despite effective in the treatment of numerous malignancies, some clinicians …

New advancements have emerged in the field of hepatocellular carcinoma (HCC) in recent
years. There has been a switch in the type of presentation of HCC in developed countries …

Deregulation of many kinases is directly linked to cancer development and the tyrosine
kinase family is one of the most important targets in current cancer therapy regimens. In this …

The epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase
that is activated by several ligands leading to the activation of diverse signaling pathways …

Targeted therapies by means of compounds that inhibit a specific target molecule represent
a new perspective in the treatment of cancer. In contrast to conventional chemotherapy …

Hepatocellular carcinoma (HCC) is a leading cause of death among cirrhotic patients and
has become a major health problem in developed countries. There is an elemental …

Hepatocellular carcinoma (HCC), one of the most common cancers worldwide, is often
diagnosed at an advanced stage when most potentially curative therapies such as resection …